WING C CHAN, MD
Medical Practice at Nebraska Medical Ctr, Omaha, NE
License number
Nebraska 18377
Category
Osteopathic Medicine
Type
Hematology
License number
Nebraska 18377
Category
Medical Practice
Type
Anatomic Pathology & Clinical Pathology
Address
Address
988102 Nebraska Medical Ctr, Omaha, NE 68198
Phone
(402) 559-4186
(402) 559-6018 (Fax)
(402) 559-6018 (Fax)
Organization information
See more information about WING C CHAN at bizstanding.comWing C Chan
Universty Of Nebraska Med Ct, Omaha, NE 68198
Categories:
Child Development Centers
Phone:
(402) 559-7684 (Phone)
University Of Nebraska Medical Center - Wing C Chan MD
983135 Nebraska Medical Ctr, Omaha, NE 68198
Categories:
Government Contractors, Physicians & Surgeons
Phone:
(402) 559-4186 (Phone)
Professional information
See more information about WING C CHAN at trustoria.com
Dr. Wing C Chan - MD (Doctor of Medicine)
Dr. Wing C Chan - MD (Doctor of Medicine)
Hospitals:
South 42Nd St, Omaha 68198
988102 Nebraska Medical Ctr, Omaha 68198
UNIVERSITY OF NEBRASKA MED CTR
983135 Nebraska Medical Ctr, Omaha 68198
South 42Nd St, Omaha 68198
988102 Nebraska Medical Ctr, Omaha 68198
UNIVERSITY OF NEBRASKA MED CTR
983135 Nebraska Medical Ctr, Omaha 68198
988102 Nebraska Medical Ctr, Omaha 68198
UNIVERSITY OF NEBRASKA MED CTR
983135 Nebraska Medical Ctr, Omaha 68198
South 42Nd St, Omaha 68198
988102 Nebraska Medical Ctr, Omaha 68198
UNIVERSITY OF NEBRASKA MED CTR
983135 Nebraska Medical Ctr, Omaha 68198
Education:
Medical Schools
The Chinese University of Hong Kong / Faculty of Medicine
The Chinese University of Hong Kong / Faculty of Medicine
Wing C Chan, Omaha NE
Wing C Chan, Omaha NE
Specialties:
Pathologist
Address:
988102 Nebraska Medical Ctr, Omaha, NE 68198
Omaha, NE 68198
Omaha, NE 68198
Methods For Identifying, Diagnosing, And Predicting Survival Of Lymphomas
Methods For Identifying, Diagnosing, And Predicting Survival Of Lymphomas
US Patent:
8131475, Mar 6, 2012
Filed:
Jul 25, 2006
Appl. No.:
11/493387
Inventors:
Louis M. Staudt - Silver Spring MD, US
George Wright - Rockville MD, US
Sandeep Dave - Washington DC, US
Bruce Tan - Baltimore MD, US
John I. Powell - Ijamsville MD, US
Wyndham Wilson - Washington DC, US
Elaine Jaffe - Great Falls VA, US
Wing C. Chan - Omaha NE, US
Timothy C. Greiner - Council Bluffs IA, US
Dennis Weisenburger - Elkhom NE, US
James Armitage - Omaha NE, US
Kai Fu - Omaha NE, US
Richard I. Fisher - Pittsford NY, US
Lisa Rimsza - Tucson AZ, US
Thomas Miller - Tucson AZ, US
Thomas Grogan - Tucson AZ, US
Elias Campo - Barcelona, ES
Silvia M Bea - Sabadell, ES
Itziar Salaverria - Barcelona, ES
Armando Lopez-Guillermo - Barcelona, ES
Emili Montserrat - Barcelona, ES
Victor Moreno - Barcelona, ES
Andreas Zettl - Würzburg, DE
German Ott - Würzburg, DE
Hans-Konrad Muller-Hermelink - Wuerzburg, DE
Andreas Rosenwald - Wuerzburg, DE
Julie Vose - Omaha NE, US
Randy Gascoyne - North Vancouver, CA
Joseph Connors - Vancouver, CA
Erlend Smeland - Oslo, NO
Stein Kvaløy - Oslo, NO
Harald Holte - Oslo, NO
Jan Delabie - Oslo, NO
T. Andrew Lister - London, GB
George Wright - Rockville MD, US
Sandeep Dave - Washington DC, US
Bruce Tan - Baltimore MD, US
John I. Powell - Ijamsville MD, US
Wyndham Wilson - Washington DC, US
Elaine Jaffe - Great Falls VA, US
Wing C. Chan - Omaha NE, US
Timothy C. Greiner - Council Bluffs IA, US
Dennis Weisenburger - Elkhom NE, US
James Armitage - Omaha NE, US
Kai Fu - Omaha NE, US
Richard I. Fisher - Pittsford NY, US
Lisa Rimsza - Tucson AZ, US
Thomas Miller - Tucson AZ, US
Thomas Grogan - Tucson AZ, US
Elias Campo - Barcelona, ES
Silvia M Bea - Sabadell, ES
Itziar Salaverria - Barcelona, ES
Armando Lopez-Guillermo - Barcelona, ES
Emili Montserrat - Barcelona, ES
Victor Moreno - Barcelona, ES
Andreas Zettl - Würzburg, DE
German Ott - Würzburg, DE
Hans-Konrad Muller-Hermelink - Wuerzburg, DE
Andreas Rosenwald - Wuerzburg, DE
Julie Vose - Omaha NE, US
Randy Gascoyne - North Vancouver, CA
Joseph Connors - Vancouver, CA
Erlend Smeland - Oslo, NO
Stein Kvaløy - Oslo, NO
Harald Holte - Oslo, NO
Jan Delabie - Oslo, NO
T. Andrew Lister - London, GB
Assignee:
The United States of America as represented by the Secretary, Department of Health and Human Services - Washington DC
Board of Regents of the University of Nebraska - Lincoln NE
University of Rochester - Rochester NY
Arizona Board of Regents of Behalf of the University of Arizona - Tucson AZ
Universitat de Barcelona - Barcelona
Fundacio Clinic - Barcelona
Hospital Clinic - Barcelona
Julius-Maximilians-University of Wuerzburg - Wuerzburg
British Columbia Cancer Agency Branch - Vancouver
Oslo University Hospital HF - Oslo
Queen Mary and Westfield College, University of London - London
Board of Regents of the University of Nebraska - Lincoln NE
University of Rochester - Rochester NY
Arizona Board of Regents of Behalf of the University of Arizona - Tucson AZ
Universitat de Barcelona - Barcelona
Fundacio Clinic - Barcelona
Hospital Clinic - Barcelona
Julius-Maximilians-University of Wuerzburg - Wuerzburg
British Columbia Cancer Agency Branch - Vancouver
Oslo University Hospital HF - Oslo
Queen Mary and Westfield College, University of London - London
International Classification:
G01N 33/48, C12Q 1/68, G06G 7/58
US Classification:
702 19, 435 6, 702 20, 703 11
Abstract:
Gene expression data provides a basis for more accurate identification and diagnosis of lymphoproliferative disorders. In addition, gene expression data can be used to develop more accurate predictors of survival. The present invention discloses methods for identifying, diagnosing, and predicting survival in a lymphoma or lymphoproliferative disorder on the basis of gene expression patterns. The invention discloses a novel microarray, the Lymph Dx microarray, for obtaining gene expression data from a lymphoma sample. The invention also discloses a variety of methods for utilizing lymphoma gene expression data to determine the identity of a particular lymphoma and to predict survival in a subject diagnosed with a particular lymphoma. This information will be useful in developing the therapeutic approach to be used with a particular subject.
Methods For Identifying, Diagnosing, And Predicting Survival Of Lymphomas
Methods For Identifying, Diagnosing, And Predicting Survival Of Lymphomas
US Patent:
2012022, Sep 6, 2012
Filed:
Mar 1, 2012
Appl. No.:
13/409416
Inventors:
Louis M. Staudt - Silver Spring MD, US
George Wright - Rockville MD, US
Sandeep Dave - Washington DC, US
Bruce Tan - Baltimore MD, US
John I. Powell - Ijamsville MD, US
Wyndham Wilson - Washington DC, US
Elaine Jaffe - Great Falls VA, US
Wing C. Chan - Omaha NE, US
Timothy C. Greiner - Council Bluffs IA, US
Dennis Weisenburger - Elkhorn NE, US
James Armitage - Omaha NE, US
Kai Fu - Omaha NE, US
Richard I. Fisher - Pittsford NY, US
Lisa Rimsza - Tucson AZ, US
Thomas Miller - Tucson AZ, US
Thomas Grogan - Tucson AZ, US
Elias Campo - Barcelona, ES
Silvia M. Bea - Sabadell, ES
Itziar Salaverria - Barcelona, ES
Armando Lopez-Guillermo - Barcelona, ES
Emili Montserrat - Barcelona, ES
Victor Moreno - Barcelona, ES
Andreas Zetti - Wurzburg, DE
German Ott - Wurzburg, DE
Hans-Konrad Muller-Hermelink - Wuerzburg, DE
Andreas Rosenwald - Wuerzburg, DE
Julie Vose - Omaha NE, US
Randy Gascoyne - North Vancouver, CA
Joseph Connors - Vancouver, CA
Erlend Smeland - Oslo, NO
Stein Kvaloy - Oslo, NO
Harald Holte - Oslo, NO
Jan Delabie - Oslo, NO
T. Andrew Lister - London, GB
George Wright - Rockville MD, US
Sandeep Dave - Washington DC, US
Bruce Tan - Baltimore MD, US
John I. Powell - Ijamsville MD, US
Wyndham Wilson - Washington DC, US
Elaine Jaffe - Great Falls VA, US
Wing C. Chan - Omaha NE, US
Timothy C. Greiner - Council Bluffs IA, US
Dennis Weisenburger - Elkhorn NE, US
James Armitage - Omaha NE, US
Kai Fu - Omaha NE, US
Richard I. Fisher - Pittsford NY, US
Lisa Rimsza - Tucson AZ, US
Thomas Miller - Tucson AZ, US
Thomas Grogan - Tucson AZ, US
Elias Campo - Barcelona, ES
Silvia M. Bea - Sabadell, ES
Itziar Salaverria - Barcelona, ES
Armando Lopez-Guillermo - Barcelona, ES
Emili Montserrat - Barcelona, ES
Victor Moreno - Barcelona, ES
Andreas Zetti - Wurzburg, DE
German Ott - Wurzburg, DE
Hans-Konrad Muller-Hermelink - Wuerzburg, DE
Andreas Rosenwald - Wuerzburg, DE
Julie Vose - Omaha NE, US
Randy Gascoyne - North Vancouver, CA
Joseph Connors - Vancouver, CA
Erlend Smeland - Oslo, NO
Stein Kvaloy - Oslo, NO
Harald Holte - Oslo, NO
Jan Delabie - Oslo, NO
T. Andrew Lister - London, GB
Assignee:
The United States of America, as Represented by the Secretary, Dept. of Health and Human Services - Bethesda MD
Board of Regents of the University of Nebraska - Lincoln NE
University of Rochester - Rochester NY
Arizona Board of Regents on Behalf of the University of Arizona - Tucson AZ
Universitat De Barcelona - Barcelona
Queen Mary and Westfield College, University of London - London
Hospital Clinic - Barcelona
Julius-Maximilians-University of Wuerzburg - Wrzburg
British Columbia Cancer Agency Branch - Vancover
Oslo University Hospital HE - Oslo
Fundacio Clinic - Barcelona
Board of Regents of the University of Nebraska - Lincoln NE
University of Rochester - Rochester NY
Arizona Board of Regents on Behalf of the University of Arizona - Tucson AZ
Universitat De Barcelona - Barcelona
Queen Mary and Westfield College, University of London - London
Hospital Clinic - Barcelona
Julius-Maximilians-University of Wuerzburg - Wrzburg
British Columbia Cancer Agency Branch - Vancover
Oslo University Hospital HE - Oslo
Fundacio Clinic - Barcelona
International Classification:
C40B 30/04
US Classification:
506 9
Abstract:
Gene expression data provides a basis for more accurate identification and diagnosis of lymphoproliferative disorders. In addition, gene expression data can be used to develop more accurate predictors of survival. The present invention discloses methods for identifying, diagnosing, and predicting survival in a lymphoma or lymphoproliferative disorder on the basis of gene expression patterns. The invention discloses a novel microarray, the Lymph Dx microarray, for obtaining gene expression data from a lymphoma sample. The invention also discloses a variety of methods for utilizing lymphoma gene expression data to determine the identity of a particular lymphoma and to predict survival in a subject diagnosed with a particular lymphoma. This information will be useful in developing the therapeutic approach to be used with a particular subject.